ESMO: TIL therapy improves on Yervoy in melanoma trial
(NEWS PROVIDED BY Pharmaphorum, September 11, 2022, Phil Taylor) A personalised cell therapy based on tumour-infiltrating lymphocyte (TIL) cells has…











Copyright © 2014-2022 - AIM at Melanoma Foundation. All rights reserved. Website by RED ZEPHYR DESIGN